Page 3 - Marie Campinell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cue Biopharma s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Cue Biopharma s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

United statesMarie campinellJonathan pappasAlexander dimitrios colevasStanford cancer centerLifesci communicationsStanford university school of medicineStanford universityCorporate communicationsCue biopharma incCue biopharmaNeck cancers symposiumStanford university schoolSelective targeting

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMarie campinellDaniel passeriMaya romanchuckLifesci communicationsCue biopharma incCorporate communicationsOncology summitCue biopharmaSelective targeting

Cue Biopharma To Present At The JMP Securities Hematology And Oncology Summit

Cue Biopharma To Present At The JMP Securities Hematology And Oncology Summit
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel passeriMarie campinellCorporate communicationsCue biopharma incOncology summitCue biopharmaSelective targeting

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms Tumor 1 Positive Cancers at SITC 2023 -November 03, 2023 at 12:01 pm EDT

Overall response rate of 47% and disease control rate of 65% in first line recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® ORR of 56% in patients with low expression of.

United statesSan diegoDan passeriMatteo levisettiJennifer eva selfridgeMaya romanchukChristine chungMarie campinellLifesci communicationsSociety for immunotherapy of cancerMoffitt cancer centerCue biopharma incUniversity hospitals cleveland medical centerCorporate communicationsDepartment of headH lee moffitt cancer center

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting

BOSTON, Sept. 27, 2023 Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T.

San diegoUnited statesChristine chungMarie campinellJennifer eva selfridgeMaya romanchukCorporate communicationsSecurities exchangeLifesci communicationsH lee moffitt cancer centerDrug administrationCue biopharma incSociety for immunotherapy of cancerUniversity hospitals cleveland medical centerAnniversary annual meetingMoffitt cancer center